Evidence map›Paper›PMID 41781019›Full record

ArticleJournal for immunotherapy of cancer2026

Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8

Yang Yang, Junjian He, Texi Liang, Kaiyi Li, Yao Lin, Hairu Wang, Wenwen Xi, Shusen Ye, Ding Qiu, Chunyang Xie and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yang Yang *Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
Junjian He *Institute of Immunology, Third Military Medical University, Chongqing, China.
Texi Liang *Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
Kaiyi Li *Institute for Immunology and Pathogenesis, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
Yao LinDepartment of Urology, South China Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Hairu WangInstitute of Immunology, Third Military Medical University, Chongqing, China.
Wenwen XiInstitute of Immunology, Third Military Medical University, Chongqing, China.
Shusen YeInstitute for Immunology and Pathogenesis, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
Ding QiuInstitute for Immunology and Pathogenesis, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
Chunyang XieGuangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
Yaxing HaoInstitute of Immunology, Third Military Medical University, Chongqing, China.
Teming LiDepartment of General Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, China chenxiangyu@cqmu.edu.cn li_teming@126.com yskedda0604@163.com yelilinlcmv@tmmu.edu.cn.
Shuai YueCancer Center, Daping Hospital and Army Medical Center of PLA, Third Military Medical University, Chongqing, China chenxiangyu@cqmu.edu.cn li_teming@126.com yskedda0604@163.com yelilinlcmv@tmmu.edu.cn.
Lilin YeGuangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China chenxiangyu@cqmu.edu.cn li_teming@126.com yskedda0604@163.com yelilinlcmv@tmmu.edu.cn.
Xiangyu ChenDepartment of Rheumatology and Immunology, Center for Immune Ageing and Rejuvenation, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China chenxiangyu@cqmu.edu.cn li_teming@126.com yskedda0604@163.com yelilinlcmv@tmmu.edu.cn.ORCID http://orcid.org/0000-0001-7947-3211

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of combined chemotherapy and programmed cell death protein-1 (PD-1) immune checkpoint blockade (ICB) is constrained by the collateral cytotoxicity of chemotherapy toward proliferating tumor-specific CD8

methodsBy using the murine acutely resolved lymphocytic choriomeningitis virus (LCMV) infection and tumor models (colorectal cancer and melanoma), we characterized the susceptibility of CD8

resultsWe first demonstrated that within the tumor microenvironment, CD8

conclusionsOur study establishes the chemotherapy-resistant CD8

Indexed as

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsImmunotherapyOncolytic VirotherapyProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorCombined Modality TherapyFemaleHumansLymphocytic choriomeningitis virusMiceMice, Inbred C57BLImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorChemotherapyImmune Checkpoint InhibitorOncolytic virusT cellViral-specific T cells

Identifiers

PMID41781019
PMCPMC12970110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.